Real-World Studies
Effectiveness of an on-site vaccination campaign for patients with cancer
Markus et alBMC Public Health
Patients with hematological or oncological malignancies are at a heightened risk for severe infectious complications, making routine immunization a crucial preventive strategy. Although National Immunization Technical Advisory Groups recommend routine vaccines for this population, real-world uptake remains suboptimal. To evaluate strategies to bridge this gap, a pre- and post-observational study assessed a 1.5-year multi-component intervention campaign at the University Hospital Cologne in Germany. The campaign integrated patient education, healthcare staff training, direct on-site vaccination access, and targeted promotional outreach covering COVID-19, influenza, herpes zoster, pneumococci, and RSV.
The study included 749 oncology patients (398 at baseline in 2023 and 351 post-intervention in 2025). Following the implementation of the campaign, overall vaccination coverage increased from 43% to 49%. Specific vaccine rates showed marked improvements: pneumococcal vaccination rose from 16% to 36%, herpes zoster coverage increased from 22% to 33%, and influenza vaccination rose from 37% to 48%. COVID-19 vaccine coverage maintained a high baseline throughout, staying above 90%. Furthermore, the proportion of patients fully vaccinated according to national public health recommendations increased nearly threefold from 6% to 16%, while the proportion of completely unvaccinated patients shifted slightly from 4% to 6%. These results indicate that dedicated, hospital-based vaccination campaigns effectively boost vaccine coverage among cancer patients, though significant gaps in schedule completion remain.
Key Takeaways
- An on-site multi-component vaccination campaign increased overall vaccine uptake among cancer patients from 43% to 49% and raised full adherence to recommended public health immunization schedules from 6% to 16%.
- Specific vaccine coverage improved substantially for pneumococcal (16% to 36%), herpes zoster (22% to 33%), and influenza (37% to 48%) vaccines, while COVID-19 vaccination rates remained consistently above 90%.
- Despite targeted patient and staff educational efforts, 84% of oncology patients remained incompletely vaccinated per recommended guidelines post-intervention, with completely unvaccinated rates shifting from 4% to 6%.
Read the original sourceBMC Public Health
